Head-To-Head Comparison: ALT5 Sigma (AIFC) vs. Its Peers

ALT5 Sigma (NASDAQ:AIFC) is one of 341 public companies in the “Financial Services” industry, but how does it weigh in compared to its competitors? We will compare ALT5 Sigma to related businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Risk & Volatility

ALT5 Sigma has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s competitors have a beta of 2.50, meaning that their average share price is 150% more volatile than the S&P 500.

Profitability

This table compares ALT5 Sigma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-409.63%	-16.12%	-6.09%

Earnings and Valuation

This table compares ALT5 Sigma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	0.60
ALT5 Sigma Competitors	$9.17 billion	$1.07 billion	8.51

ALT5 Sigma’s competitors have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ALT5 Sigma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1974	6879	11622	443	2.50

As a group, “Financial Services” companies have a potential downside of 3.83%. Given ALT5 Sigma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe ALT5 Sigma has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 21.7% of shares of all “Financial Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ALT5 Sigma competitors beat ALT5 Sigma on 12 of the 12 factors compared.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.